Gholami Ali, Sohrabi Masoudreza, Baradaran Hamid Reza, Hariri Mitra
Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Department of Epidemiology and Biostatistics, School of Public Health, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Biol Trace Elem Res. 2024 Dec 13. doi: 10.1007/s12011-024-04486-w.
Chromium has been recognized for its beneficial effects on inflammation reduction; therefore, we conducted a systematic review and meta-analysis to find the effect of chromium supplementation on serum levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) in subjects aged 18 years and older. Related articles were identified by searching databases such as the Cochrane Library, ClinicalTrials.gov, ISI Web of Science, Scopus, and PubMed up until Agust 2024. We computed the mean differences (MD) along with their standard deviations (SDs) to carry out the meta-analysis. Statistical heterogeneity of the intervention effects was assessed using I-squared statistics and Cochran's Q test. In total, twelve and eleven studies were included in the present systematic review and meta-analysis, respectively. The pooled results indicated that the differences in serum levels of CRP and TNF-α between chromium group and the comparison group were statistically significant (CRP: weighted mean difference (WMD) = -0.58 mg/L; 95% confidence interval (CI) = -0.95, -0.22 mg/L; P = 0.002; TNF-α: WMD = -1.22 pg/ml; 95% CI = -1.91, -0.53 pg/ml; p = 0.001). In contrast, chromium supplementation resulted in a non-significant decrease in serum levels of IL-6 (WMD = -0.63 pg/ml; 95% CI: -1.67, 0.4 pg/ml; P < 0.001). Our study supports the beneficial effect of chromium supplementation on serum concentration of CRP and TNF-α, but our results showed that chromium supplementation non-significantly reduced the serum levels of IL-6. However, it seems that chromium formulation, participants' BMI, sample size, and geographical region are strong variables that predict the effect of chromium supplementation on inflammatory mediators.
铬因其在减轻炎症方面的有益作用而受到认可；因此，我们进行了一项系统评价和荟萃分析，以探究补充铬对18岁及以上受试者血清C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）和白细胞介素-6（IL-6）水平的影响。通过检索Cochrane图书馆、ClinicalTrials.gov、ISI科学网、Scopus和PubMed等数据库，直至2024年8月，确定了相关文章。我们计算了平均差异（MD）及其标准差（SD）以进行荟萃分析。使用I²统计量和Cochrane Q检验评估干预效果的统计异质性。本系统评价和荟萃分析分别纳入了12项和11项研究。汇总结果表明，铬组与对照组之间血清CRP和TNF-α水平的差异具有统计学意义（CRP：加权平均差异（WMD）=-0.58mg/L；95%置信区间（CI）=-0.95，-0.22mg/L；P=0.002；TNF-α：WMD=-1.22pg/ml；95%CI=-1.91，-0.53pg/ml；P=0.001）。相比之下，补充铬导致血清IL-6水平非显著下降（WMD=-0.63pg/ml；95%CI：-1.67，0.4pg/ml；P<0.001）。我们的研究支持补充铬对血清CRP和TNF-α浓度的有益作用，但我们的结果表明补充铬非显著降低了血清IL-6水平。然而，铬制剂、参与者的体重指数、样本量和地理区域似乎是预测补充铬对炎症介质影响的重要变量。
